High-dose cisplatin as neoadjuvant organ-preserving chemotherapy for squamous cell carcinoma of the larynx

Cancer Journal from Scientific American

Volumn 2, Issue 1, 1996, Pages 46-51

  Lacava, Juan A ^a,b   Ferreyra, Rubén ^a   Leone, Bernardo A ^a   Losada, Carlos ^a   Elem, Yuly L ^a   Vallejo, Carlos T ^a  

^a Grupo Oncologico Cooperativo del Sur   (Argentina)

^b GOCS Neuquén ^*  (Argentina)

Author keywords

High dose cisplatin; Laryngeal cancer; Neoadjuvant therapy

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LARYNX TUMOR; MALE; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; SQUAMOUS CELL CARCINOMA; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 2842595985     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Shah JP, Tollefsen HR. Epidermoid carcinoma of the supraglottic larynx: role of the neck dissection in initial surgical treatment. Am J Surg 1974;128:494-498.
2. Hawkins NV. The treatment of glottic carcinoma: an analysis of 800 cases. Laryngoscope 1975;85:1485-1493.
3. Jesse RH. The evaluation of treatment of patients with extensive squamous cancer of the vocal cords. Laryngoscope 1975;85:1424-1429.
4. Lansky SB, List MA, Ritter-Sterr C, Logemann J, Pecis K. Quality of life in head and neck cancer survivors. Proc Am Soc Clin Oncol 1989;8:169.
5. Harwood AR, Rawlinson E. The quality of life of patients following treatment for advanced laryngeal cancer. Int J Radiat Oncol Biol Phys 1983;9:335-338.
6. McNeil BJ, Weichselbaum R, Pauker SG. Speech and survival: tradeoffs between quality and quantity of life in laryngeal cancer. N Engl J Med 1981;305:982-987.
7. Vikram B, Wittes R, Fee WE et al. Adjuvant chemotherapy for advanced head and neck squamous carcinoma: final report of the Head and Neck Contracts program. Cancer 1987;60:301-308.
8. Schuller DE, Metch B, Mattox D, Stein DW, McCraken JD. Preoperative chemotherapy in advanced resectable head and neck cancer: final report of the Southwest Oncology Group. Laryngoscope 1988;98:1205-1212.
9. Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiotherapy compared with surgery plus radiotherapy in patients with advanced laryngeal cancer. N Engl J Med 1991;324:1685-1690.
10. Spaulding MB, Fisher SG, Wolf GT, Department of Veterans Affairs Laryngeal Cooperative Cancer Study Group. Tumor response, toxicity, and survival after neoadjuvant organ-preserving chemotherapy for advanced laryngeal carcinoma. J Clin Oncol 1994;12:1592-1599.
11. Schaeffer SD, Middleton R, Reisch J, Frenkel EP. Cis-platinum induction chemotherapy in the multi-modality initial treatment of advanced stage IV carcinoma to the head and neck. Cancer 1983;51:2168-2174.
12. Hong WK, Shapshay S, Bhutani R et al. Induction chemotherapy in advanced squamous head and neck cancer with high-dose cisplatin and bleomycin infusion. Cancer 1979;44:19-25.
13. Wittes R, Cvitkovic E, Shah J, Gerold FP, Strong EW. Cis-dichlorodiammineplatinum (II) in the treatment of epidermoid carcinoma of the head and neck. Cancer Treat Rep 1977;61:359-366.
14. Wittes R, Brescia F, Young CW, Magill GB, Golbey RB, Krakoff IH. Combination chemotherapy with cis-diamminedichloroplatinum (II) and bleomycin in tumors of head and neck. Oncology 1975;32:202-207.
15. Ozols RF, Corden BJ, Jacob J, Wesley MN, Ostchega Y, Young R. High dose cisplatin in hypertonic saline. Ann Intern Med 1984;100:19-25.
16. Ozols RF, Deisseroth AB, Javadpour N, Barlock A, Messerschmidt GL, Young RC. Treatment of poor prognosis nonseminomatous testicular cancer with a "high dose" platinum combination chemotherapy regimen. Cancer 1983;51:1803-1807.
17. Gralla RJ, Casper ES, Kelsen DP et al. Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: a randomized trial investigating two dosage schedules. Ann Intern Med 1981;95:414-420.
18. Samson MK, Rivkin SE, Jones SE et al. Dose-response and dose-survival advantage for high versus low-dose cisplatinum combined with vinblastine and bleomycin in disseminated testicular cancer. A Southwest Oncology Group study. Cancer 1984;53:1029-1035.
19. Forastiere AA, Hakes TB, Wittes JT et al. Cisplatin in the treatment of metastatic breast cancer carcinoma. A prospective randomized trial of two dosage schedules. Am J Clin Oncol 1982;5:243-247.
20. Ozols RF, Ostchega Y, Myers CE, Young RC. High-dose cisplatin in hypertonic saline in refractory ovarian cancer. J Clin Oncol 1985;3:1246-1250.
21. Litterst CL. Alterations in the toxicity of cis-diamminedichloroplatinum (II) and in tissue localization of platinum as a function of NacL concentration in the vehicle of administration. Toxicol Appl Pharmacol 1981;61:99-108.
22. 2) in hypertonic saline. Proc Am Soc Clin Oncol 1985;4:179.
23. Gandara DR, DeGregorio MW, Wold H et al. High-dose cisplatin in hypertonic saline: reduced toxicity of a modified dose schedule and correlation with plasma pharmacokinetics. A Northern California Oncology Group pilot study in non-small-cell lung cancer. J Clin Oncol 1986;4:1787-1793.
24. Livingston RB. Cisplatin in the treatment of solid tumors: effect of dose and schedule. J Natl Cancer Inst 1989;81:724-725.
25. American Joint Committee on Cancer Staging and End-Results Reporting (AJC). Manual for Staging of Cancer. 3rd ed. Philadelphia: J. B. Lippincott, 1988:115-121.
26. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-214.
27. Perry MC. Appendix: WHO toxicity guidelines. In Perry MC, ed. The Chemotherapy Source Book. Baltimore: Williams & Wilkins, 1992:1132-1144.
28. Kaplan EC, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:437-481.
29. Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 1984;2:1281-1288.
30. Simes RJ, Zelen M. Exploratory data analysis and the use of the hazard function for interpreting survival data: an investigator's primer. J Clin Oncol 1985;3:1418-1431.
31. Forastiere AA, Takasugi BJ, Baker SR, Wolf GT, Kudla-Hatch V. High-dose cisplatin in advanced head and neck cancer. Cancer Chemother Pharmacol 1987;19:155-158.
32. Mortimer JE, Taylor ME, Schulman S, Cunnings C, Weymuller E, Jr, Laramore G. Feasibility and efficacy of weekly intraarterial cisplatin in locally advanced (stage III and IV) head and neck cancers. J Clin Oncol 1988;6:969-975.
33. Havlin KA, Khun JG, Myers JW et al. High-dose cisplatin for locally advanced or metastatic head and neck cancer. Cancer 1989;63:423-427.
34. Thomas Robbins K, Storniolo AM, Kerber C et al. Phase I study of highly selective supradose cisplatin infusions for advanced head and neck cancer. J Clin Oncol 1994;12:2113-2120.
35. Haines I, Bosl G, Pfister D et al. Very-high-dose cisplatin with bleomycin infusion as initial treatment of advanced head and neck cancer. J Clin Oncol 1987;5:1594-1600.
36. Forastiere AA, Belliveau JF, Goren MP, Vogel WC, Posner MR, O'Leary GP, Jr. Pharmacokinetic and toxicity evaluation of five-day continuous infusion versus intermittent bolus cis-diamminedichloroplatinum (II) in head and neck cancer patients. Cancer Res 1988;48:3869-3874.
37. Al-Kourainy K, Kish J, Ensley J et al. Achievement of superior survival for histologically negative versus histologically positive clinically complete responders to cisplatin combination in patients with locally advanced head and neck cancer. Cancer 1987;59:233-238.
38. Stupp R, Weichselbaum R, Vokes EE. Combined modality therapy of head and neck cancer. Semin Oncol 1994;21:349-358.